Scholarlink

Background <p>Several metabolic disorders have been linked to chronic hepatitis C virus (HCV) infection, especially HCV related hepatic steatosis, insulin resistance, and lipid dysregulation. We aimed at comparing the effects of treatment of HCV direct-acting antivirals (DAAs) alone versus DAAs combined with metformin or lifestyle modifications on improving glycemic control and reducing hepatic steatosis in prediabetic patients chronically infected with HCV.</p> Methods <p>We enrolled 150 chronic HCV-infected patients with confirmed diagnosis of prediabetes [glycosylated hemoglobin (HbA1c) = 5.7–6.4%] and hepatic steatosis as measured by controlled attenuation parameter (CAP). The patients were randomly divided into 3 groups, group 1 received DAAs only, group 2 received DAAs combined with lifestyle modifications, and group 3 received DAAs with metformin. Liver steatosis at baseline and at sustained virological response (SVR) 12, body mass index (BMI), and glycemic parameters were assessed.</p> Results <p>Out of 150 patients, 148 patients completed the study and achieved SVR12. At baseline, no differences in demographic, laboratory, liver steatosis characteristics were seen between the 3 groups. At SVR12, glycemic parameters improved significantly in all 3 groups while steatosis significantly decreased in groups 2 (<i>p</i> &lt; 0.001) and 3 (<i>p</i> = 0.014) only. Comparing the delta change of CAP, BMI, HbA1c, and fasting blood sugar (FBS) among the 3 groups showed significant differences (<i>p</i> = 0.004, <i>p</i> &lt; 0.001, <i>p</i> = 0.007, <i>p</i> = 0.006 respectively). Pairwise group comparison showed superiority of groups 2 and 3 in improving glycemic state while liver steatosis improvement was maximum in group 2.</p> Conclusion <p>Combining DAAs with lifestyle modifications or metformin in HCV-infected patients with prediabetes and hepatic steatosis can significantly improve glycemic control and steatosis compared to DAAs alone.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Impact of combining metformin or lifestyle modifications with direct-acting antivirals on hepatic steatosis and glycemic control in HCV prediabetic patients

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月16日

查看全文
  • Reham Abdelmoniem,
  • Karim Mohamed Akl,
  • Hend Shousha,
  • Naglaa Elsaid,
  • Rania Kamal Darwish,
  • Rabab Fouad,
  • Omnia Tantawi

摘要

Background

Several metabolic disorders have been linked to chronic hepatitis C virus (HCV) infection, especially HCV related hepatic steatosis, insulin resistance, and lipid dysregulation. We aimed at comparing the effects of treatment of HCV direct-acting antivirals (DAAs) alone versus DAAs combined with metformin or lifestyle modifications on improving glycemic control and reducing hepatic steatosis in prediabetic patients chronically infected with HCV.

Methods

We enrolled 150 chronic HCV-infected patients with confirmed diagnosis of prediabetes [glycosylated hemoglobin (HbA1c) = 5.7–6.4%] and hepatic steatosis as measured by controlled attenuation parameter (CAP). The patients were randomly divided into 3 groups, group 1 received DAAs only, group 2 received DAAs combined with lifestyle modifications, and group 3 received DAAs with metformin. Liver steatosis at baseline and at sustained virological response (SVR) 12, body mass index (BMI), and glycemic parameters were assessed.

Results

Out of 150 patients, 148 patients completed the study and achieved SVR12. At baseline, no differences in demographic, laboratory, liver steatosis characteristics were seen between the 3 groups. At SVR12, glycemic parameters improved significantly in all 3 groups while steatosis significantly decreased in groups 2 (p < 0.001) and 3 (p = 0.014) only. Comparing the delta change of CAP, BMI, HbA1c, and fasting blood sugar (FBS) among the 3 groups showed significant differences (p = 0.004, p < 0.001, p = 0.007, p = 0.006 respectively). Pairwise group comparison showed superiority of groups 2 and 3 in improving glycemic state while liver steatosis improvement was maximum in group 2.

Conclusion

Combining DAAs with lifestyle modifications or metformin in HCV-infected patients with prediabetes and hepatic steatosis can significantly improve glycemic control and steatosis compared to DAAs alone.